We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $962M
1-Year Est. Return 524.64%
This Fund
S&P 500
This Quarter Est. Return
+33.44%
1 Year Est. Return
+524.64%
3 Year Est. Return
+2,765.44%
5 Year Est. Return
+10,523.08%
10 Year Est. Return
–
AUM
$962M
AUM Growth
-$17.7M
Cap. Flow
-$105M
Cap. Flow %
-10.94%
Top 10 Hldgs %
42.32%
Holding
98
New
25
Increased
18
Reduced
27
Closed
25

Top Buys

Rank Stock Value
1
ELVN icon
Enliven Therapeutics
ELVN
+$20.8M
2
SGMT icon
Sagimet Biosciences
SGMT
+$19.9M
3
ASND icon
Ascendis Pharma A/S
ASND
+$19.1M
4
CELC icon
Celcuity
CELC
+$16.5M
5
ORKA
Oruka Therapeutics
ORKA
+$13.5M

Top Sells

Rank Stock Value
1
KALV
KalVista Pharmaceuticals
KALV
+$57.9M
2
NUVL
Nuvalent
NUVL
+$36.4M
3
DNTH icon
Dianthus Therapeutics
DNTH
+$23.1M
4
CNTA
Centessa Pharmaceuticals
CNTA
+$18.5M
5
KOD icon
Kodiak Sciences
KOD
+$17.3M

Sector Composition

Rank Sector Weight
1 Healthcare 91.68%
2 Miscellaneous 6.61%
3 Financials 1.7%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
ARTV
51
Artiva Biotherapeutics
ARTV
$542M
$5.09M 0.53%
+525,000
New +$4.78M
CTNM
52
Contineum Therapeutics
CTNM
$641M
$4.85M 0.5%
296,135
-5,594
-2% -$73.3K
QURE icon
53
uniQure
QURE
$3.38B
$4.84M 0.5%
+105,000
New +$2.75M
RACC
54
Research Alliance Corp III
RACC
$195M
$3.85M 0.4%
+360,000
New +$3.75M
ABEO icon
55
Abeona Therapeutics
ABEO
$339M
$3.77M 0.39%
610,407
-38,535
-6% -$212K
INSM icon
56
Insmed
INSM
$25.9B
$3.67M 0.38%
34,438
-1,412
-4% -$171K
KPTI icon
57
Karyopharm Therapeutics
KPTI
$42.4M
$2.91M 0.3%
+297,460
New +$2.58M
KYMR icon
58
PUT
Kymera Therapeutics
KYMR
$9.82B
$2.87M 0.3%
+25,000
New +$2.15M
CAMP icon
59
CAMP4 Therapeutics
CAMP
$260M
$2.86M 0.3%
653,594
– –
ELUT icon
60
Elutia
ELUT
$39M
$2.15M 0.22%
2,192,980
-305,040
-12% -$324K
RVMD icon
61
Revolution Medicines
RVMD
$44.6B
$1.87M 0.19%
+10,000
New +$1.46M
SION
62
Sionna Therapeutics
SION
$265M
$1.87M 0.19%
42,478
+3,061
+8% +$122K
ABSI icon
63
PUT
Absci
ABSI
$1.49B
$1.83M 0.19%
+157,600
New +$888K
TELA icon
64
TELA Bio
TELA
$31.4M
$1.6M 0.17%
2,137,201
-122,111
-5% -$99.9K
ACHV icon
65
Achieve Life Sciences
ACHV
$834M
$1.48M 0.15%
+227,178
New +$1.08M
FULC icon
66
CALL
Fulcrum Therapeutics
FULC
$294M
$1.43M 0.15%
391,900
– –
GUTS icon
67
Fractyl Health
GUTS
$105M
$1.3M 0.14%
1,637,976
-63,649
-4% -$45.3K
CNTB
68
Connect Biopharma Holdings
CNTB
$140M
$1.3M 0.13%
+545,000
New +$1.32M
CBIO
69
Crescent Biopharma
CBIO
$659M
$1.06M 0.11%
59,104
-71,396
-55% -$1.39M
CLRB icon
70
Cellectar Biosciences
CLRB
$23.9M
$894K 0.09%
+321,728
New +$900K
FHTX icon
71
Foghorn Therapeutics
FHTX
$356M
$224K 0.02%
+45,975
New +$204K
ADGM
72
Adagio Medical Holdings
ADGM
$11.3M
$146K 0.02%
224,360
-27,612
-11% -$27K
RCKTW icon
73
Rocket Pharmaceuticals Warrant
RCKTW
$74.7K
$356 ﹤0.01%
104,828
– –
ANNX icon
74
Annexon
ANNX
$942M
– –
-496,461
Closed -$2.75M
CELC icon
75
CALL
Celcuity
CELC
$4.33B
– –
-54,500
Closed -$6.22M
1 2
3
4

Similar funds

LGP
Leonard Green & Partners Los Angeles, California $962M AUM 35.11% 1-Year Est. Return
PL
Parthenon LLC Louisville, Kentucky $962M AUM 27.46% 1-Year Est. Return
LAM
L2 Asset Management Wayland, Massachusetts $963M AUM 38.06% 1-Year Est. Return
ACP
Aviance Capital Partners Naples, Florida $963M AUM 32.56% 1-Year Est. Return
GIG
Goodnow Investment Group Darien, Connecticut $964M AUM 2.51% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
BEAM
Baker Ellis Asset Management Vancouver, Washington $964M AUM 39.24% 1-Year Est. Return
RAM
Ramirez Asset Management New York $960M AUM 30.25% 1-Year Est. Return

Silverarc Capital Management's Q2 2026 Portfolio in Review

As of Q2 2026, Silverarc Capital Management held 98 positions worth $962M, down 1.8% from $980M the previous quarter. Its ten largest holdings account for 42% of the portfolio.

Silverarc Capital Management withdrew a net $105M in Q2 2026, closing 25 positions and reducing 27 holdings. Its most notable exit was KalVista Pharmaceuticals, an estimated $57.9M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 92% of assets, up from 85% a quarter earlier, followed by Miscellaneous and Financials.

Against the trend, Silverarc Capital Management opened a new position in Enliven Therapeutics worth $24.8M.

  • Silverarc Capital Management's largest Q2 2026 buy was Enliven Therapeutics: 489,382 shares worth $24.8M.
  • Silverarc Capital Management added most to Ascendis Pharma A/S in Q2 2026, an estimated $19.1M increase.
  • Silverarc Capital Management's biggest Q2 2026 reduction was Dianthus Therapeutics, cutting an estimated $23.1M.
  • Silverarc Capital Management fully exited KalVista Pharmaceuticals in Q2 2026, selling an estimated $57.9M.
  • Silverarc Capital Management's ten largest holdings make up 42% of its $962M portfolio in Q2 2026.
  • Silverarc Capital Management opened 25 new positions and closed 25 in Q2 2026.
  • Silverarc Capital Management's portfolio value fell 1.8% quarter-over-quarter to $962M.

Based on Silverarc Capital Management's 13F filing for Q2 2026, filed 13 Aug 2026.